Biological marker Lyso-GL1 in Gaucher disease type 1 as a key to successful diagnosis, monitoring of clinical course and treatment of an orphan disease
DOI:
https://doi.org/10.15574/SP.2025.1(145).7074Keywords:
biological marker, anemia, thrombocytopenia, hepatosplenomegaly, bone lesions, lesions of internal organsAbstract
Gaucher disease type 1 (GD 1) is a hereditary disease caused by a deficiency of the enzyme glucocerebrosidase, which leads to the accumulation of glucocerebroside in cells, especially in macrophages. The disease affects the spleen, liver, bones and bone marrow. One of the key diagnostic markers is glucosylsphingosine (Lyso-GL1), which reflects the accumulation of glucocerebroside and indicates the presence of GD1. Lyso-GL1 is important for early diagnosis, monitoring disease progression and assessing the effectiveness of therapy. A decrease in the level of this biomarker during treatment indicates its success, which allows adjusting drug doses and predicting the patient's response to therapy.
Aim - to determine the importance of studying the Lyso-GL1 biomarker in the diagnosis and monitoring of GD1.
Material and methods. Lyso-GL1 levels were analyzed in 27 children with GD1 aged 11 months to 21 years from 2014 to 2024 to assess the effectiveness of treatment, optimize the results of enzyme replacement therapy with imiglucerase, and improve the individual approach.
Results. Lyso-GL1 levels can be a prognostic indicator of the risk of developing organ damage or complications. Patients with higher Lyso-GL1 levels have a higher risk of developing hematopoietic system failure (anemia, thrombocytopenia), serious damage to both internal organs (enlarged liver and spleen), and bones (presence of bone pain and bone crises), which indicates the prevalence of this marker not only for monitoring therapy, but also for predicting the course of the disease.
Conclusions. Lyso-GL1 level is an important and reliable tool for the diagnosis and treatment of GD1. Its use in clinical practice significantly affects the accuracy of diagnosis, allows for individualization of treatment and promotes long-term monitoring without the need for frequent invasive procedures.
The study was performed in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Bioethics and Deontology Committee of the institution specified in the work. Informed consent of patients was obtained for the study.
The authors declare that there is no conflict of interest.
References
Burlina AB, Polo G, Rubert L et al. (2019). Implementation of second-tier tests in newborn screening for lysosomal disorders in North Eastern Italy. Int J Neonatal Screen. 5(2): 24. https://doi.org/10.3390/ijns5020024; PMid:33072983 PMCid:PMC7510225
Cozma C, Cullufi P, Kramp G et al. (2020). Treatment efficiency in Gaucher patients can reliably be monitored by quantification of Lyso-Gb1 concentrations in dried blood spots. Int J Mol Sci. 21(13): 4577. https://doi.org/10.3390/ijms21134577; PMid:32605119 PMCid:PMC7369829
Dinur T, Grittner U, Revel-Vilk S, et al. (2021). Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-Gb1) values in patients with type 1 Gaucher disease: statistical models for comparing three enzymatic formulations. Int J Mol Sci. 22(14): 7699. https://doi.org/10.3390/ijms22147699; PMid:34299318 PMCid:PMC8307068
Dupuis L, Chipeaux C, Bourdelier E et al. (2020). Effects of sphingolipids overload on red blood cell properties in Gaucher disease. J Cell Mol Med. 24(17): 9726-9736. https://doi.org/10.1111/jcmm.15534; PMid:32767726 PMCid:PMC7520281
FDA-NIH Biomarker Working Group. 2022. BEST (Biomarkers, EndpointS, and other Tools). URL: https://www.ncbi.nlm.nih.gov/books/NBK326791/.
Hurvitz N, Dinur T, Becker-Cohen M et al. (2019). Glucosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease. Int J Mol Sci. 20(12): 3033. https://doi.org/10.3390/ijms20123033; PMid:31234327 PMCid:PMC6627663
Irun P, Cebolla JJ, Lopez de Frutos L et al. (2020). LC-MS/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population. Clin Chem Lab Med. 58(5): 798-809. https://doi.org/10.1515/cclm-2019-0949; PMid:32126008
Lukina E, Watman N, Dragosky M et al. (2019). Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the Phase 2 trial. Am J Hematol. 94(1): 29-38. https://doi.org/10.1002/ajh.25300; PMid:30264864 PMCid:PMC6587500
Mistry PK, Lukina E, Ben Turkia H et al. (2021). Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results. Am J Hematol. 96(9): 1156-1165. https://doi.org/10.1002/ajh.26276; PMid:34161616 PMCid:PMC8457136
Nair S, Bar N, Xu ML, et al. (2020). Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Mol Genet Metab. 129(4): 286-291. https://doi.org/10.1016/j.ymgme.2020.01.009; PMid:32044242 PMCid:PMC8223251
Peterschmitt MJ, Foster MC, Ji AJ, Zajdel MB, Cox GF. (2023). Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1. Mol Genet Metab. 138(3): 107527. https://doi.org/10.1016/j.ymgme.2023.107527; PMid:36739645
Revel-Vilk S, Fuller M, Zimran A. (2020). Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review. Int J Mol Sci. 21(19): 7159. https://doi.org/10.3390/ijms21197159; PMid:32998334 PMCid:PMC7584006
Sam R, Ryan E, Daykin E. (2021). Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opin Pharmacother. 22(11): 1489-1503. https://doi.org/10.1080/14656566.2021.1902989; PMid:33711910 PMCid:PMC8373623
Saville JT, McDermott BK, Chin SJ et al. (2020). Expanding the clinical utility of glucosylsphingosine for Gaucher disease. J Inherit Metab Dis. 43(3): 558-563. https://doi.org/10.1002/jimd.12192; PMid:31707742
Schiffmann R, Sevigny J, Rolfs A, et al. (2020). The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 43(5): 1056-1059. https://doi.org/10.1002/jimd.12235; PMid:32242941 PMCid:PMC7540563
Stiles AR, Huggins E, Fierro L et al. (2021). The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease. Mol Genet Metab Rep. 27: 100729. https://doi.org/10.1016/j.ymgmr.2021.100729; PMid:33614410 PMCid:PMC7876627
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
